Pharmaceutical compositions containing sc(Fv)2
The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.
1. A pharmaceutical sc(Fv)2 composition,
wherein the sc(Fv)2 in the composition has four variable regions V1-V4 connected by three peptide linkers, arranged in order: V1, linker 1, V2, linker 2, V3, linker 3, V4;
wherein each of linkers 1 and 3 is at least 15 amino acids in length;
wherein either
(a) V1 and V3 are heavy chain variable domains and V2 and V4 are light chain variable domains, or
(b) V1 and V3 are light chain variable domains and V2 and V4 are heavy chain variable domains;
wherein the sc(Fv)2 can exist in the form of at least two alternate conformational isomers, the two conformational isomers being
(A) a bivalent scFv-type sc(Fv)2 in which V1 is associated with V2, and V3 is associated with V4, and
(B) a single chain diabody type sc(Fv)2 in which V1 is associated with V4, and V2 is associated with V3;
wherein at least 80% of the sc(Fv)2 in the composition is in the form of one of the two alternate conformational isomers (the “specific conformational isomer”); and
wherein the pharmaceutical composition comprises meglumine.
2. The pharmaceutical composition of claim 1 , wherein the composition has a pH of 4.5 to 9.0.
3. The pharmaceutical composition of claim 1 , wherein the composition has a pH of 6.0 to 9.0.
4. The pharmaceutical composition of claim 1 , wherein the composition has a salt concentration of 50 mM to 1000 mM.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a freeze-dried formulation.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a spray-dried formulation.
7. The pharmaceutical composition of claim 1 , wherein the specific conformational isomer constitutes 90% or more of the sc(Fv)2 present in the pharmaceutical sc(Fv)2 composition.
8. The pharmaceutical composition of claim 1 , wherein the specific conformational isomer constitutes 95% or more of the sc(Fv)2 present in the pharmaceutical sc(Fv)2 composition.
9. The pharmaceutical composition of claim 1 , wherein the specific conformational isomer is a bivalent scFv-type sc(Fv)2.
10. The pharmaceutical composition of claim 1 , wherein the specific conformational isomer is a single chain diabody type sc(Fv)2.
11. A pharmaceutical sc(Fv)2 composition,
wherein the sc(Fv)2 in the composition has four variable regions V1-V4 connected by three peptide linkers, arranged in order: V1, linker 1, V2, linker 2, V3, linker 3, V4;
wherein each of linkers 1 and 3 is at least 15 amino acids in length;
wherein either
(a) V1 and V4 are light chain variable domains and V2 and V3 are heavy chain variable domains, or
(d) V1 and V4 are heavy chain variable domains and V2 and V3 are light chain variable domains;
wherein the sc(Fv)2 is in the form of a bivalent scFv-type sc(Fv)2 in which V1 is associated with V2, and V3 is associated with V4;
wherein at least 80% of the sc(Fv)2 in the composition is in the form of the bivalent scFv-type sc(Fv)2; and
wherein the pharmaceutical composition comprises meglumine.
12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises histidine buffer.
13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises mannitol.
14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises lysine.
15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises citric acid buffer.
16. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition further comprises histidine buffer.
17. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition further comprises mannitol.
18. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition further comprises lysine.
19. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition further comprises citric acid buffer.